1047630-72-7

Basic information

• Product Name: Methyl 4-broMo-5-chlorothiophene-2-carboxylate
• Synonyms: Methyl 4-broMo-5-chlorothiophene-2-carboxylate;4-Bromo-5-chloro-2-thiophenecarboxylic acid methyl ester;2-Thiophenecarboxylic acid, 4-bromo-5-chloro-, methyl ester;methyl 4-bromo-5-chloro-2-thiophenecarboxylate
• CAS NO: 1047630-72-7
• Molecular Formula: C₆H₄BrClO₂S
• Molecular Weight: 255.51676
• EINECS: -0
• Mol File: 1047630-72-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 293.9±35.0 °C(Predicted)
• Appearance: /
• Density: 1.762±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: Methyl 4-broMo-5-chlorothiophene-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-broMo-5-chlorothiophene-2-carboxylate(1047630-72-7)
• EPA Substance Registry System: Methyl 4-broMo-5-chlorothiophene-2-carboxylate(1047630-72-7)

Safety Data

• Hazardous Substances Data: 1047630-72-7(Hazardous Substances Data)

Usage

General Description

Methyl 4-bromo-5-chlorothiophene-2-carboxylate is a chemical compound with the molecular formula C8H6BrClO2S. It is an organic compound that contains a thiophene ring with bromine and chlorine substituents, as well as a carboxylate functional group. Methyl 4-broMo-5-chlorothiophene-2-carboxylate is often used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has also been studied for its potential biological and therapeutic activities. Methyl 4-bromo-5-chlorothiophene-2-carboxylate is a colorless to pale yellow liquid with a slightly fruity odor and is used in various research and industrial applications.

Upstream product

• 62224-24-2 2,3-dibromothiophene-5-carboxylic acid methyl ester 
• 24065-33-6 5-Chlorothiophene-2-carboxylic acid 
• 35475-03-7 methyl 5-chloro-2-thiophenecarboxylate 

Downstream Products

• 1047630-52-3 methyl 5-chloro-4-(1-methylpyrazol-5-yl)-2-thiophenecarboxylate 
• 1047630-61-4 5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxylic acid 
• 1047645-80-6 5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-N-{(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}-2-thiophenecarboxamide 
• 1047644-62-1 N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl] ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide 
• 1047645-87-3 N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-5-chloro-4-(4-fluoro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide trifluoroacetate 
• 1047645-88-4 N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-5-chloro-4-(4-fluoro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride 
• 1047645-82-8 N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride 
• 1047645-86-2 5-chloro-N-((1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-4-(4-fluoro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide 
• 1047645-78-2 N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride 
• 1047628-44-3 4-(4-bromo-1-methyl-1H-pyrazol-5-yl)-5-chloro-N-{(1S)-2-cyclohexyl-1-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]ethyl}-2-thiophenecarboxamide 
• 1047628-41-0 5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-N-{(1S)-2-cyclohexyl-1-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]ethyl}-2-thiophenecarboxamide 
• 1047644-90-5 N-[(1S)-2-amino-1-(phenylmethyl)ethyl]-5-chloro-4-(1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride 
• 1047628-35-2 5-chloro-N-{(1S)-2-cyclohexyl-1-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]ethyl}-4-(1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide 
• 1047645-75-9 5-chloro-N-{(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}-4-(1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide 

Relevant articles and documents

Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors

Heteroaromatic carboxamides of formula (I), wherein Y, R, and X are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of formula (I) can be used in methods for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.

INHIBITORS OF AKT ACTIVITY

-